Objective-The urokinase-type plasminogen activator (uPA) and its specific receptor (uPAR) are a potent multifunctional system involved in vascular remodeling. The goal of the study was to unravel the mechanisms of uPA/uPAR-directed vascular smooth muscle cell (VSMC) differentiation. Methods and Results-Using cultured human primary VSMCs, we identified a new molecular mechanism controlling phenotypic modulation in vitro and in vivo. We found that the urokinase-type plasminogen activator receptor (uPAR) acts together with the transcriptional coactivator myocardin to regulate the VSMC phenotype. uPAR, a glycosylphosphatidylinositol-anchored cell-surface receptor family member, undergoes ligand-induced internalization and nuclear transport in VSMCs. Platelet-derived growth factor receptor ␤ and SUMOylated RanGAP1 mediate this trafficking. Nuclear uPAR associates with myocardin, which is then recruited from the promoters of serum response factor target genes and undergoes proteasomal degradation. This chain of events initiates the synthetic VSMC phenotype. Using mouse carotid artery ligation model, we show that this mechanism contributes to adverse vascular remodeling after injury in vivo. We then cultured cells on a microstructured biomaterial and found that substrate topography induced uPAR-mediated VSMC differentiation. Conclusion-These findings reveal the transcriptional activity of uPAR, controlling the differentiation of VSMCs in a vascular disease model. They also suggest a new role for uPAR as a therapeutic target and as a marker for VSMC phenotyping on prosthetic biomaterials. (Arterioscler Thromb Vasc Biol. 2012;32:110-122.)
uPAR are induced after vascular injury and promote neointima formation in atherosclerosis. 3 The uPA/uPAR system controls VSMC migration and proliferation and fibrin deposition, and it interferes with wound healing. 4 The uPAR also influences remodeling-related inflammation. 5, 6 uPAR and uPAR-dependent intracellular signaling regulate the epithelial-mesenchymal transition 7 and fibroblast-tomyofibroblast differentiation. 8 We observed earlier that uPAR is an active regulator of VSMC phenotypic changes. 9, 10 We suggested that upregulated uPAR expression at vascular injury sites could serve for VSMC transition from their physiological contractile to the pathophysiological synthetic phenotype. However, the mechanism by which uPAR may interfere with regulation of contractile protein expression is not known.
uPA is a proteolytic enzyme mediating plasminogen activation. 11 Because uPAR is linked to the outer membrane leaflet by a glycosylphosphatidylinositol anchor and has no transmembrane and cytoplasmic domains, uPAR's diverse biological functions are strictly dependent on its interactions with other proteins. Thus, the uPAR "interactome" includes membrane proteins, soluble factors present in the pericellular space, and partners in the extracellular matrix. 11 As a result, uPAR activates numerous intracellular signaling molecules leading to proliferative, migratory, adhesive, and apoptotic responses. 11 In VSMCs, uPAR is associated with platelet- Figure 1 . Urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) regulates expression of contractile proteins via myocardin. A, Expression of smooth muscle ␣-actin (SMA) and calponin mRNAs in uPAR siRNA or uPA siRNA-nucleofected vascular smooth muscle cells (VSMCs) (left) and in VSMCs stimulated with uPA for 3 hours (right), analyzed by TaqMan. Both were normalized to GAPDH. B, Expression of SMA (left) and calponin (right) mRNAs in wild-type (WT) and uPAϪ/Ϫ aortic VSMCs infected with uPARsi or control lentivirus, analyzed by TaqMan. Expression of both was normalized to 18S RNA. C, Myocardin protein expression in human VSMCs after uPARsi. D, Expression of myocardin after 3 hours of VSMC stimulation with uPA. The lower panel shows quantification of the Western blotting data. E, SMA-or SM22␣-specific promoter activity in uPARsi VSMCs measured by luciferase assay. F, Association of myocardin with serum response factor (SRF) was studied using nuclear coimmunoprecipitation (co-IP). IP indicates immunoprecipitation. G, SMA-or SM22␣-specific promoter activity in VSMCs overexpressing DDK-myocardin measured by luciferase assay. H, SRF association with SMA and smooth muscle myosin heavy chain (SM-MHC) promoters studied by chromatin immunoprecipitation. Control and myocardin overexpressing cells were stimulated with uPA for 1 hour. derived growth factor receptor ␤ (PDGFR␤), which serves as a transmembrane adaptor to mediate intracellular signaling and cellular responses. 12 uPAR also controls VSMC proliferative phenotype through the transcription factor Stat1, whereas uPAR signals a migratory behavior through Tyk2, phosphatidylinositol 3-kinase, and the Rho family of proteins. [13] [14] [15] VSMC differentiation marker genes are regulated by serum response factor (SRF), a transcription factor that binds to conserved promoter CArG boxes. 16, 17 Myocardin is a recently identified coactivator of SRF-dependent transcription exclusively expressed in cardiac and VSMC lineages 18 that is required for VSMC differentiation. 19 Myocardin selectively induces expression of CArG-dependent VSMC marker genes, including smooth muscle ␣-actin (SMA), smooth muscle myosin heavy chain, SM22␣, and calponin. 20 Mice lacking myocardin die during midembryogenesis from a lack of differentiated VSMCs. 21 Remarkably, forced expression of myocardin in fibroblasts is sufficient to activate the VSMC differentiation program. 22 We explored the hypothesis that myocardin is involved in the uPAR-directed VSMC phenotypic changes. We found that uPAR inhibits myocardindependent smooth muscle gene expression and transcriptional activity. Unexpectedly, this mechanism requires uPAR nuclear translocation and its direct interaction with myocardin in vitro and in vivo. We identify the uPAR-myocardin axis as 
Figure 3
Urokinase-type plasminogen activator receptor (uPAR) and myocardin associate in cell nucleus in a urokinase-type plasminogen activator (uPA)-dependent manner. A, Vascular smooth muscle cells (VSMCs) stimulated with uPA for 1 and 2 hours a new regulatory mechanism of the VSMC differentiation and dedifferentiation program on vascular remodeling.
Methods

Cell Culture and Transfections
Human VSMCs were isolated from umbilical arteries using the explant technique in VascuLife SMC cell culture medium (CellSystems Biotechnologie Vertrieb GmbH). VSMCs were used between passages 2 and 4. Aortic VSMCs from uPAϪ/Ϫ, uPARϪ/Ϫ and corresponding wild-type control animals were isolated by enzymatic digestion as described earlier. 23 Primary VSMCs were transfected using Amaxa Nucleofector I (Lonza Group Ltd) and the Human Primary Smooth Muscle Cells Basic Nucleofection Kit (Lonza Group Ltd) according to the manufacturer's instructions. Lentiviral infection of mouse VSMCs was performed as described. 24 The constructs to express luciferase under SMA and SM22␣ promoters were a generous gift of Dr G. Owens (University of Virginia School of Medicine). Constructs to express glutathione S-transferase-fusion mutants of myocardin were kindly given by Dr Jiliang Zhou (Albany Medical College). Vector for expression of DDK-tagged myocardin was purchased from Origene (RC229055).
Biochemical Methods
Subcellular fractionation was performed using Subcellular Protein Fractionation Kit (Pierce, Thermo Scientific). Coimmunoprecipitation (co-IP) of nuclear proteins was studied using the Nuclear Complex Co-IP kit (Active Motif). Biotinylation of surface proteins was performed using 2 mg/mL sulfo-N-hydroxysulfosuccinimide-SS-biotin in PBS. Biotinylated cells were then stimulated with uPA and incubated at 37°C to allow internalization. Reduction of proteins remained on the plasma membrane allowed detection of internalized proteins only. Luciferase activity was measured using Promega ONE-Glo luciferase assay system according to the manufacturer's instructions. 20S proteasome activity was measured fluorimetrically using the assay kit from Cayman Chemical Company using SUC-LLVY-AMC as a substrate.
Chromatin Immunoprecipitation Assay and Reverse Transcription-Polymerase Chain Reaction
Chromatin immunoprecipitation analysis was performed using Sim-pleChIP Enzymatic Chromatin IP kit (Cell Signaling Technology). Anti-SRF antibody was used for immunoprecipitation, and then SRF association with SMA and smooth muscle myosin heavy chain promoters was estimated using SYBR Green reverse transcriptionpolymerase chain reaction. The total RNA for quantitative reverse transcription-polymerase chain reaction was isolated from VSMCs using the RNeasy miniprep kit (Qiagen). Real-time quantitative reverse transcription-polymerase chain reaction was performed on a LightCycler 480 Real-Time PCR System using LightCycler 480 RNA Master Hydrolysis probes (Roche Diagnostics GmbH).
Immunofluorescence
For immunocytochemical staining, we relied on paraformaldehydefixed, Triton X-100 -permeabilized cells cultured on glass coverslips. As DNA stains, we used either DraQ5 or 4Ј,6-diamidino-2-phenylindole. The confocal cell images were captured using a Leica TCS-SP2 AOBS confocal microscope (Leica Microsystems). For the details of cell staining for fluorescence resonance energy transfer (FRET) analysis and images acquisition and analysis, please refer to the supplemental material, available online at http://atvb.ahajournals.org.
Immunocytochemistry and Immunohistochemistry
Cells were blocked with 3% BSA and labeled with primary antibody (2 hours at room temperature) and fluorescently labeled secondary antibodies (1 hour at room temperature). As DNA stains, either DraQ5 or 4Ј,6-diamidino-2-phenylindole was used. Frozen sections were blocked with 5% goat serum and incubated with anti-uPAR (M-17) antibody (Santa Cruz Biotechnology) in blocking solution overnight and chicken anti-goat Alexa 488 antibody for 1 hour at room temperature. Cells nuclei were labeled with DraQ5, and slides were mounted using Aqua Poly/Mount medium (Polysciences).
Mouse Carotid Artery Ligation
The mouse carotid artery ligation model was performed as described. 25 Animal experiments were approved by the regulatory board for animal welfare of the state of Niedersachsen, Germany.
Microstructured Substrates
Microstructured cell substrates were fabricated from organically modified ceramics (ORMOCER, Microresist GmbH), a silicatebased inorganic-organic hybrid polymer, by 2-photon polymerization with femtosecond pulses. 26, 27 VSMCs cultivated on plane and structured ORMOCER were fixed and stained similarly to cells cultivated on glass coverslips.
Statistics
Data were analyzed for statistical significance using the 2-tailed Student t test for independent samples (OriginPro 8 SRO). Data are presented as meanϮSEM. Differences were considered statistically significant at a value of PϽ0.05.
For a detailed description, please refer to the supplemental material.
Results
Myocardin Is Involved in uPAR-Directed VSMC Phenotypic Changes
Our previous observations showed that uPAR is involved in VSMC phenotypic regulation. Downregulation of uPAR expression using small interfering RNA gene silencing (uPARsi) in human VSMCs (Supplemental Figure IA ) resulted in increased activity of smooth muscle promoters 10 and increased expression of contractile proteins mRNAs, such as SMA and calponin ( Figure 1A , left). In vivo, infiltrating cells serve as a source of uPA at sites of vascular injury. In cell culture, VSMCs produce both uPA and uPAR. 9 We reasoned that the effect of receptor silencing could be explained by an inhibition of autocrine uPA/uPAR action directed to cell switch to synthetic phenotype and proliferation. We then used Because uPAR exhibits also ligand-independent functions, 28 we downregulated uPAR expression in aortic VSMCs from uPAϪ/Ϫ mice with lentiviral-based uPARsi to confirm that changes in VSMC phenotype are directed by uPAdependent uPAR activation. The expression of contractile proteins was elevated in VSMCs isolated from uPAϪ/Ϫ mice compared with wild-type control cells ( Figure 1B ). Although expression of contractile proteins was slightly increased after uPARsi in uPAϪ/Ϫ cells, receptor silencing had no additive effect. This result suggests that uPA and uPAR act together to downregulate contractile protein expression in VSMCs.
Myocardin is expressed in human umbilical artery VSMCs, and its downregulation indeed decreased the expression of contractile proteins, such as SMA and calponin (Supplemental Figure IC-IF). To investigate the potential role of myocardin in uPA/uPAR-directed VSMC phenotypic changes, we first examined effects of uPAR downregulation on myocardin. Western blotting and reverse transcription-polymerase chain reaction analysis showed that the protein level of myocardin was markedly upregulated in uPARsi cells, whereas uPA stimulation decreased it ( Figure 1C and 1D ). mRNA level of myocardin was not upregulated by uPARsi but was decreased after uPA treatment in a uPAR-dependent manner (Supplemental Figure IG) . Similarly, myocardin expression in VSMCs isolated from uPARϪ/Ϫ mice was comparable to wild-type and downregulated by uPA in a uPAR-dependent manner (Supplemental Figure IG) .
To determine whether or not the uPA/uPAR system could directly affect myocardin-dependent transcriptional activity, luciferase assays were performed with SMA and SMA22␣ promoters in cells stimulated with uPA. uPA decreased promoter activity in a uPAR-dependent manner ( Figure 1E ). Myocardin transactivates smooth muscle marker gene expression by physically interacting with SRF on promoters of smooth muscle genes. Therefore, decrease of myocardin protein level should result in changes of SRF transcriptional activity. We addressed this question by studying myocardin/ SRF interaction using co-IP analysis. We observed a timedependent dissociation of myocardin/SRF complex in response to cell stimulation with uPA ( Figure 1F ). To confirm further the involvement of myocardin in uPA/uPARmediated events, we overexpressed human DDK-tagged myocardin in VSMCs (Supplemental Figure IH and II). In myocardin-overexpressing VSMCs, uPA failed to downregulate promoter activity of contractile proteins ( Figure 1G ). Accordingly, the decreased SRF association with smooth muscle gene promoters after uPA treatment observed in chromatin immunoprecipitation assay was also prevented by myocardin overexpression ( Figure 1H) .
Together, the above data demonstrate that uPA and uPAR affect the formation of the SRF/myocardin/CArG complex.
uPAR Promotes Myocardin Proteasomal Degradation
To address the mechanisms used by the uPA/uPAR system to regulate the myocardin protein levels, we performed immunocytochemical staining of myocardin in human VSMCs (Figure 2A ). When the cells were stimulated with uPA, myocardin redistributed within nucleus and accumulated in nuclear bodies that look like clastosomes that are enriched in proteasomal subunits. 29 When stained with 26S proteasome antibodies, these structures indeed revealed colocalization of myocardin and proteasomes ( Figure 2B ). The number of cells containing clastosome-like structures increased with uPA stimulation ( Figure 2C ). When the cells were treated with the proteasome inhibitor AM-114, the uPA-induced decrease of myocardin protein was abolished ( Figure 2D ). The data suggest that 30 to 60 minutes after uPA application the SRF/myocardin complex dissociates and myocardin is degraded. Accordingly, AM-114 treatment prevented downregulation of contractile protein expression in TaqMan analysis ( Figure 2E ). Because proteasomal degradation of myocardin has been reported, 30, 31 we studied whether or not uPA induces myocardin ubiquitination and found that it was increased by uPA ( Figure 2F ). These data support our assumption that the effect of uPAR on myocardin protein might be mediated through proteasomal degradation.
uPAR Translocates to the Cell Nucleus and Associates With Myocardin
We performed immunocytochemistry and unexpectedly observed that uPA induced uPAR translocation to cell nucleus ( Figure 3A and Supplemental Figure II) . Similar results were obtained using mouse aortic VSMCs (Supplemental Figure  IIIA) . To characterize intracellular redistribution of uPAR and myocardin in response to uPA further, we stained human VSMCs and then created image intensity profiles using ImageJ software. uPA treatment led first to uPAR translocation to cell nucleus and then to the clastosomes, where uPAR colocalized with myocardin ( Figure 3A ). We used confocal microscopy to localize uPAR at serial planes of the cell nucleus (Supplemental Figure IIC) . 3D reconstruction of clastosome-containing cell nuclei stained for uPAR and myocardin showed colocalization of proteins in clastosomelike structures, with uPAR being localized in the core of the structure. Video obtained from serial confocal images is available as the supplemental video. These data clearly demonstrate ligand-induced uPAR nuclear translocation in VSMCs. Interestingly, this response to uPA stimulation was observed in cells at passages 2 to 3 that were stained positively for SMA-containing fibers. The number of such cells decreased progressively during cell culturing.
Next, we addressed uPA-induced uPAR and myocardin redistribution by performing isolation of subcellular fractions using a subcellular fractionation kit. We isolated cytosolic, membrane, soluble nuclear, and chromatin-bound nuclear extracts (Supplemental Figure IIIB) . Cells stimulation with uPA induced redistribution of uPAR from membrane fraction to soluble nuclear extract, which was accompanied by redistribution of myocardin from chromatin-bound nuclear extract to soluble nuclear extract ( Figure 3B) .
We observed co-IP of uPAR and myocardin from whole cell lysates ( Figure 3C ). We then performed co-IP on cytosolic fractions and nuclear extracts. The enzymatic nuclear extraction process (using a nuclear complex co-IP kit) maintains chromatin-bound and free protein complexes contained in the nucleus (Supplemental Figure IJ) . These experiments revealed uPA-induced myocardin-uPAR association in the nuclear fraction but not in the cytoplasmic fraction ( Figure 3D ).
To directly address the possibility of uPAR association with myocardin, uPAR-myocardin interaction, we used FRET. Nuclear translocation of uPAR was accompanied by the appearance of a FRET signal between myocardin and uPAR in cell nucleus and particularly in clastosomes ( Figure  3E ), confirming the direct association of the 2 proteins in cell nucleus. To characterize the interaction between uPAR and myocardin, we performed a glutathione S-transferase pulldown assay using glutathione S-transferase-myocardin fusion protein mutants. We observed that only the N-terminal part of myocardin, particularly the N-terminal domain, was required for interaction with uPAR from cell lysates of uPA-stimulated VSMCs ( Figure 3F ). Accordingly, in nuclear co-IP from VSMCs overexpressing DDK-tagged myocardin, we observed its very strong association with uPAR after uPA stimulation in nuclear co-IP using anti-DDK antibody ( Figure 3G ).
Cell Surface uPAR Undergoes Endocytosis and Nuclear Translocation
The above data demonstrated that binding of extracellular ligand uPA induced uPAR endocytosis and accumulation in nucleus. At least 2 internalization pathways have been described for uPAR. The ternary uPAR/uPA/plasminogen activator inhibitor-1 complex associates rapidly to low-density lipoprotein receptor-related protein-1 and is efficiently removed from the cell surface via clathrin-coated pits. 32, 33 Recent studies showed that uPAR might also be endocytosed by a macropinocytic mechanism coupled with rapid recycling to the cell surface independently of ligands. 34 To clarify which mechanisms are responsible for uPAR intracellular translocation in VSMCs, we first looked for evidence that membrane pool of uPAR translocates to the nucleus. We labeled cell surface proteins using sulfo-N-hydroxysulfosuccinimide-SS biotin. Reduction of the proteins after cell stimulation with uPA allowed us to distinguish internalized protein exclusively. Internalized uPAR was immunoprecipitated from nuclear extract using the nuclear complex co-IP kit followed by Western blotting with streptavidin-conjugated horseradish peroxidase ( Figure 4A ). In cells subjected to biotin reduction before uPA stimulation, nuclear uPAR was not detected by streptavidin-conjugated horseradish peroxidase, but it was detected with uPAR antibodies ( Figure 4A ). Biotinylated uPAR was also co-IP with myocardin in nuclear co-IP ( Figure 4B ). Samples subjected to reduction of cell-surface protein-bound biotin immediately after labeling contained no myocardin-associated biotinylated proteins. These results indicate that cell surface uPAR translocates to the cell nucleus in the presence of uPA. To address the nature of uPAR endocytosis, we used chlorpromazine, which inhibits the clathrin-dependent endocytic pathway, and amiloride, an inhibitor of macropinocytic pathway. 34 The selected concentrations of inhibitors inhibited internalization of fluorescein isothiocyanate-transferrin and fluorescein isothiocyanate-dextran, respectively (Supplemental Figure IVA) . Using uPA-induced degradation of myocardin as a readout of successful endocytosis/nuclear translocation of uPAR, we observed that this process was not affected by chlorpromazine but was sensitive to amiloride ( Figure 4C) . Accordingly, uPA-dependent ubiquitination of myocardin was not influenced by cell treatment with chlorpromazine but was abolished by amiloride ( Figure 4D ). When stained immunocytochemically, VSMCs revealed colocalization of uPAR with early endosomal antigen in response to uPA but not in response to the amino-terminal fragment of uPA lacking the proteolytic activity ( Figure 4E ). Interestingly, uPAR also colocalized with PDGFR␤ in endosomes ( Figure 4F) , and uPA-dependent myocardin degradation was sensitive to cell treatment with the PDGFR␤ tyrosine kinase inhibitor AG 1295, as well as silencing of PDGFR␤ ( Figure  4G ). Activation of PDGFR␤ by ligand binding leads to receptor internalization and commonly to degradation by either lysosomal or proteasomal activity. 35 The observation that the amino-terminal fragment of uPA, which can induce PDGFR␤-dependent signaling in VSMCs 12 failed to induce internalization of uPAR ( Figure 4E) , suggests that PDGFR␤mediated signaling and uPAR-dependent myocardin degradation most probably represent different steps of uPA/uPARinduced intracellular events in VSMCs.
uPAR Nuclear Import Is Mediated by SUMOylated RanGAP1
We next addressed the intracellular mechanism responsible for the uPA stimulated nuclear uPAR import. The small GTP-binding protein Ran is involved in the majority of nucleocytoplasmic transport pathways. 36 In turn, Ran GTPase activating protein 1 (RanGAP1) activity regulates the activity of Ran. In vertebrate cells, this mechanism requires Ran-GAP1 modification by the small ubiquitin-like modifier (SUMO1). 36 To analyze the role of RanGAP1 in uPAR nuclear translocation, we first addressed the question of whether or not uPA is able to initiate association of uPAR and RanGAP1 on cell stimulation. Indeed, we observed co-IP of both proteins in response to uPA in a time-dependent fashion ( Figure 5A ). Under these conditions, RanGAP1 underwent SUMOylation by SUMO1 ( Figure 5B ). Kinetics of the uPA-induced uPAR-RanGAP1 association and those of Ran-GAP1 SUMOylation suggest that this mechanism might mediate uPAR nuclear import. Thus, RanGAP1 SUMOylation reached maximum at 30 minutes of uPA stimulation, whereas its association with uPAR was observed at 45 to 60 minutes, and uPAR was found in the nucleus after 1 hour. The uPAR complex with PDGFR␤, which was formed rapidly after uPA stimulation, dissociated before uPAR came into interaction with RanGAP1 (Supplemental Figure IVB) . We next analyzed the requirement of RanGAP1 for uPAR nuclear import in VSMC after RanGAP1 downregulation using small interfering RNA gene silencing (RanGAP1si) (Supplemental Figure IVC) . RanGAP1 downregulation strongly inhibited uPAR nuclear translocation and uPA-induced myocardin degradation ( Figure 5C-5E ). Collectively, these results indicate that uPA initiates RanGAP1 modification by SUMO1 and that SUMOylated RanGAP1 promotes uPAR nuclear import.
uPAR Mediates VSMC Phenotypic Changes After Vascular Remodeling In Vivo
To evaluate the in vivo pathophysiological relevance of our findings, we used a vascular injury animal model by performing carotid artery ligation in mice. After an early phase of inflammatory cell recruitment, medial VSMCs undergo switching from contractile to synthetic phenotype and rapidly proliferate and migrate toward the lumen, leading to extensive neointima formation in this model. uPAR-deficient mice and the corresponding wild-type control animals were used. No morphological differences were observed in sham carotid artery cross-sections of wild-type and uPARϪ/Ϫ mice. Morphometric analysis of media thickness performed on stained frozen sections of uPARϪ/Ϫ, and wild-type animals revealed significant differences between the mice as early as day 3. From day 3 to day 28, medial and neointima areas were further increased in wild-type mice, whereas uPARϪ/Ϫ revealed much less vascular remodeling ( Figure 6A-6C) .
TaqMan analysis performed 24 hours after carotid ligation demonstrated 20-fold upregulation of uPAR expression in ligated vessel of wild-type animals ( Figure 6D ). Increased content of uPAR in ligated vessel was accompanied by nuclear localization of uPAR in ligated vessel ( Figure 6E ). Accordingly, the expression of contractile proteins in ligated carotid arteries of wild-type animals was strongly downregulated 24 hours after vessel ligation. On the contrary, in the ligated carotid arteries of uPARϪ/Ϫ mice, the decrease in contractile protein expression was far less pronounced ( Figure 6F ).
We further assessed the protein level of myocardin expression 24 hours after vessel ligation. Myocardin was decreased in wild-type mice but not in uPARϪ/Ϫ mice ( Figure 6G ), suggesting that myocardin degradation in uPAR Ϫ/Ϫ mice might be impaired. Next, we assessed total 20S proteasomal activity in aortas of wild-type and uPARϪ/Ϫ mice. Surprisingly, we observed that 20S proteasomal activity in uPARϪ/Ϫ mice was much lower than in wild-type animals ( Figure 6H ).
Nuclear uPAR Serves as a Marker for Substrate Topography-Mediated VSMC Phenotype
Increasing evidence suggests that substrate topography, independent of its biochemical and biomechanical properties, influences cell proliferation, migration, and gene expression. 37, 38 We observed that VSMCs cultivated on gridstructured biocompatible polymer ORMOCER 27 demonstrate a higher expression of contractile proteins than cells grown on nonstructured ORMOCER (Supplemental Figure IVD and IVE). Assuming that uPAR nuclear translocation is a prerequisite for the VSMC phenotypic change to a dedifferentiated state, we performed immunocytochemical studies of uPAR localization in VSMCs cultured on these substrates. As expected, we observed strong uPAR nuclear localization under the conditions of the nonstructured substrate ( Figure  6I ). Remarkably, in cells cultured on structured ORMOCER, uPAR was not localized in the cell nucleus after uPA stimulation. These data suggest that uPAR might be involved in substrate structuring-induced VSMC differentiation.
Discussion
We found that the glycosylphosphatidylinositol-anchored receptor uPAR can conduct nuclear signaling to interfere with the myocardin-controlled gene regulation of VSMC phenotypes in vitro and in vivo. Our results could have important functional implications because they point to the as yet unknown ability of uPAR to affect directly nuclear events of transcriptional regulation. We observed that uPAR is able to undergo a ligand-induced endocytosis and nuclear translocation. Our findings suggest that uPAR/myocardin interaction in the nucleus induces displacement of myocardin from SRF, thus repressing myocardin's ability to activate VSMC gene expression and leading to ubiquitin-mediated myocardin degradation via proteasomal pathway. Chromatin immunoprecipitation analysis confirmed that uPA and uPAR indeed regulate SRF association with promoters of contractile genes in a proteasome-dependent manner. We investigated the phenomenon using biochemical and imaging approaches including FRET. We show that N-terminal domain of myocardin is required for interaction with uPAR.
Several groups recently described mechanisms related to myocardin regulation of smooth muscle and cardiac gene expression via interaction with SRF. A number of factors were identified that influence myocardin/SRF binding, including the steroid receptor coactivator 3 complex, 39, 40 which identifies a site of convergence for nuclear hormone receptor-mediated and VSMC-specific gene regulation. Our data add the signal-dependent interaction of uPAR with myocardin leading to myocardin degradation by the proteasome as a novel functional partner for cell differentiation machinery.
Several types of transmembrane receptors, such as heptahelical G-protein-coupled receptors and tyrosine kinase receptors, are translocated to the nucleus, where they have activities distinct from those expressed at the cell surface. 41 However, nothing is known about any glycosylphosphatidylinositolanchored cell surface proteins that participate in nuclear import. The receptors may be imported to the nucleus using classical basic nuclear localization signal (NLS) or because of association with NLS-containing carrier proteins. 42, 43 Recently a uPARindependent nuclear translocation of its ligand uPA via NLS sequence of nucleolin has been reported. 44 We found that SUMOylated RanGAP1 is required for uPAR nuclear transport. Because the RanGAP/importin mechanism mediates nuclear localization of NLS-bearing receptors, 45 the existence of uPAR domain functioning as a noncanonical NLS might be suggested.
The next question that must be addressed is the pathway of uPAR internalization coupled to its nuclear translocation. Aside from the canonical pathway of uPAR ligand-induced endocytosis, several alternative and uncommon mechanisms of uPAR internalization exist. 34 We found that uPAR relies on PDGFR␤ for the internalization step that seems to be clathrin independent but relies on vesicles trafficking. Clathrinindependent internalization, using macropinocytosis-like internalization pathways, was reported for receptor tyrosine kinases such as PDGFR. The relatively slow rate of uPAR internalization also speaks in favor of a macropinocytosis-like mechanism. Our earlier study showed that PDGFR␤ serves as a transmembrane adaptor of uPAR in VSMCs. We showed that uPAR/ PDGFR␤ signaling does not require uPA proteolytic activity because it was fully activated by the amino-terminal fragment of uPA. 12 Interestingly, we observed here that uPA proteolytic activity is indispensable for uPAR nuclear translocation. Most probably, rapid activation of intracellular signaling and the more gradual internalization and nuclear transport of uPAR represent 2 sequential steps of the process.
The generation of mice deficient in uPA and uPAR genes has demonstrated that the severity of vascular damage is highly dependent on the fibrinolytic system. 46, 47 We and others have shown that uPAR targeting could effectively inhibit vascular remodeling after injury. 9,48,49 uPAR deficiency, however, does not compromise embryonic development of mice. 50 No histological abnormalities in arterial wall and other tissues of adult uPARϪ/Ϫ mice were observed in the absence of challenging factors such as injury or infection. Together, these observations represent an interesting, not yet fully addressed feature of uPA/uPAR system.
Despite the obvious clinical relevance of these findings, the mechanisms responsible for the observed beneficial effect of uPAR deficiency on vascular remodeling remained unknown. Our results highlight the underlying molecular mechanism and show that phenotypic modulation of VSMCs in vivo in mouse carotid artery ligation model is also a uPAR-regulated phenomenon. Thus, in uPAR gene-deleted mice, decrease of contractile protein expression was strongly impaired, which resulted in attenuated neointima formation. Our injuredvessel model underscored the idea that the uPA/uPAR system is involved in regulation of activity of proteasomes linking the plasminolytic and proteasomal systems.
VSMCs continuously interact with tissues that possess topographical surface features because of the presence of proteins embedded in the vascular wall. Bioimplants intended to restore blood flow do not have micro-or nanoscale surface features. This state of affairs could underlie an undesired device-tissue response. Our data show that topographically treated VSMCs have a distinct differentiation profile. We found that whereas uPAR exhibited nuclear localization in synthetic VSMCs on nonstructured substrate, no nuclear uPAR was observed in cells cultured on ORMOCER. These data strongly suggest that engineered nanotopographical cues may influence VSMC behavior in a manner that could be relevant for vascular stents and other vascular applications. The data further indicate that the phenotypic state of VSMCs on structured substrates involves a mechanism of uPAR nuclear transport, and therefore, uPAR promises to be a powerful tool to control tissue-bioimplantable device response.
